Overview

Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
 

---

Investment Highlights

 

 

---

 

Products

ORAMED is poised to develop a revolutionary new means of insulin delivery—an oral insulin , offering hope to nearly 200 million diabetics worldwide.

Led by a leading team of medical research scientists, Oramed is a company focused on the commercial development of proprietary oral therapies. Currently, Oramed’s main focus is the treatment of Type 2 diabetes. Going forward, Oramed hopes to discover an oral replacement for insulin injections, as well as other methods of oral delivery for drugs and vaccinations currently delivered via needles.
 

---

Research & Development

The ability to correctly self-administer doses of insulin is crucial to the long-term health of diabetics. For years, the only method patients had to deliver insulin to their bodies was by injection. But, years of research by Oramed’s highly respected team of scientists discovered a technology at the Hadassah University Hospital that has the potential to change all of that.

Up until now, the idea of insulin pills or tablets was inconceivable due to the fact that insulin, which is a protein, breaks down in the digestive system. However, Oramed’s patented technology overcame the problem of digestion as well as permeability to the intestine. This has been a major hurdle that has inhibited the development of an orally ingestible insulin for decades.

Prof. Hanoch Bar-On, a leading Diabetologist on the Oramed team, states that the route of the insulin from the swallowed pill “imitates nature” in that it passes to the liver and then to the bloodstream. Injected insulin goes straight to the bloodstream.

Preclinical studies on animals were successful, and the Oramed team is preparing for phase one clinical trials in the near future.
 

---

Market Demand

Diabetes is a common condition in which the amount of glucose (sugar) in the blood is rising because the body is unable to use it properly. This is because the body’s method of converting glucose into energy is not working as it should. Diabetes can lead to serious complications, such as heart disease, strokes, limb's amputations, eye and kidney damage, and premature death. Other ill effects also include thrombosis, painful skin ulcers and blindness. In developing countries, diabetes is the fourth-ranking cause of death.

There are two major types of diabetes. Type 1 diabetes, known as juvenile-onset diabetes, which develops when the body’s immune system destroys the cells that produce the hormone insulin that regulates blood glucose. In order to survive, people with Type 1 diabetes must have insulin injections.

Type 2 diabetes, which accounts about 90% of all diagnosed cases of diabetes, develops when the body produces less than requested insulin, or when the insulin does not work properly. Type 2 diabetes can be treated by diet alone or by a combination of diet and medication (some of the medicine stimulates the production of insulin). As the dependency on insulin or alternative medicines rise, the pancreas gradually loses its ability to produce insulin. At this stage, daily injections of insulin may become necessary.

The introduction of oral insulin for Type 2 diabetics may in fact help to reduce the dependency on insulin shots and preclude the need for repeated injections at a later stage of Type 2 diabetes.
 

Diabetes is a serious chronic illness that represents a growing worldwide epidemic. According to the World Health Organization (WHO), the number of people suffering from diabetes has risen from 30 million in 1985 to almost 200 million in 2005, with projected figures suggesting that 370 million will be affected by 2030.

In the US alone, diabetes currently affects 20.8 million people. This represents 7.0 percent of the US population. Among them 35% to 45% need insulin injections to better control their diabetes.

According to analysts at Decision Resources, the total diabetes market (oral and insulin) was about US $11 billion in 2003. This market is expected to grow to US $14 billion by 2006, and the Type 2 diabetes therapeutic market is expected to exceed US $15.3 billion in 2013.

Growth of the diabetes market will be sustained through the continued expansion of the patient population due to aging, poor diet, conducting sedentary life style and excess body weight. The number of patients diagnosed is increasing due to routine screening and enhanced awareness.

---

Recent News and Press Releases

Oramed Pharmaceuticals Announces Maiden Year Progress Report (Tue, Mar 13)

Oramed Pharmaceuticals Announces the Completion of its World Renowned Scientific Board (Thu, Feb 22)

Oramed Pharmaceuticals Inc. Adds Another Accomplished Member to Its Scientific Board (Wed, Feb 21)

Oramed Pharmaceuticals Announces the Expansion of Its Scientific Board With a Prominent American Figure in Diabetes Research (Wed, Jan 31)

ORAMED PHARMACEUTICALS INC. Financials (Fri, Jan 26)

Oramed Further Enhances World Renowned Scientific Board of Directors (Tue, Jan 16)

Oramed Pharmaceutical, Inc. Adds to its Scientific Advisory Board (Tue, Jan 9)
 

 

 

 

 

---

Management

Nadav Kidron, CEO

Mr. Kidron is an entrepreneur whose expertise includes senior executive roles in a wide range of industries. He graduated from Bar-Ilan University in Israel with a Bachelor of Law Degree. He is a member of the Israeli bar association and is currently working towards his MBA.

George Drazenovic, CFO

Mr. Drazenovic has over 10 years of experience in accounting, financial management and financial reporting. Most recently, he was the CFO for a public energy technology company with a market capitalization in excess of US $60 million. Mr. Drazenovic is a CFA, CGA and holds an MBA from the University of Notre Dame (US) and a BA in Economics from the University of British Columbia (Canada).

Miriam Kidron, PhD

Dr. Miriam Kidron is a pharmacologist and a biochemist with a PhD in biochemistry. From 1990 to the present time, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. She was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
 

---

Contacts

Oramed Pharmaceuticals, Inc.
2 Elza Street
Jerusalem, Israel 93706
Phone: 011 972-54-790 9058
Fax: 011 972-2-679 2336
Contact: Nadav Kidron, Esq.

Investor Relations:

Oramed Pharmaceuticals, Inc.
Vinisha Agnihotri
(646) 467-2252
info@oramedpharma.com
http://www.oramedpharma.com
 

---

 

 

 

 

 

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect Oramed Pharmaceuticals Inc. current expectations about its future results, performance, prospects and opportunities. Oramed Pharmaceuticals Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Oramed Pharmaceuticals Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Oramed Pharmaceuticals Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2007 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated three thousand dollars by a non-affiliated third-party, BlueWave Advisors for its efforts in presenting the ORMP profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.